scispace - formally typeset
S

Soledad Ojeda

Researcher at University of Córdoba (Spain)

Publications -  190
Citations -  3197

Soledad Ojeda is an academic researcher from University of Córdoba (Spain). The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 26, co-authored 150 publications receiving 2530 citations. Previous affiliations of Soledad Ojeda include Sofia University.

Papers
More filters
Journal ArticleDOI

Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: a randomized comparison of a simple versus complex strategy.

TL;DR: Both strategies are effective in reducing the restenosis rate, with no differences in terms of clinical outcome, and elective SB stenting seems to provide no advantages over the simpler stent jail followed by SB balloon dilation.
Journal ArticleDOI

Multicenter randomized trial of a comprehensive hospital discharge and outpatient heart failure management program.

TL;DR: Disease management programs can reduce hospitalizations in high‐risk heart failure patients, but generalizability to the population hospitalized for HF remains to be proven.
Journal ArticleDOI

Impacto de la pandemia de COVID-19 sobre la actividad asistencial en cardiología intervencionista en España

TL;DR: Oriol Rodríguez-Leor, Belén Cid-Álvarez, Soledad Ojeda, Javier Martín-Moreiras, José Ramón Rumoroso, Ramón López-Palop, Ana Serrador, Ángel Cequier, Rafael Romaguera, Ignacio Cruz, Armando Pérez de Prado, Raúl Moreno, in nombre of todos the participantes of
Journal ArticleDOI

Impact of the COVID-19 pandemic on interventional cardiology activity in Spain

TL;DR: An important reduction in the activity in interventional cardiology has been observed during the COVID-19 epidemic, and a great decrease has been detected in the number of patients treated in the STEMI networks, with the risk of increased morbidity and mortality.
Journal ArticleDOI

Drug-eluting stents for the treatment of bifurcation lesions: A randomized comparison between paclitaxel and sirolimus stents

TL;DR: Patients with bifurcation lesions treated by sirolimus showed significantly lower rates of late loss, restenosis and target lesion revascularization than patients treated with paclitaxel-eluting stents.